Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NYSE: NXTC) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and immune disorders. This page provides centralized access to official news and developments surrounding their innovative pipeline, including antibody-drug conjugates and fusion protein therapies targeting complex tumor microenvironments.
Investors and researchers will find timely updates on clinical trial progress, strategic collaborations, and regulatory milestones. Key focus areas include NC410 combination therapies for immune modulation and the B7-H4-targeting LNCB74 ADC program. The curated news collection also covers financial disclosures, manufacturing advancements, and scientific presentations.
All content is sourced directly from company releases and verified industry publications. Bookmark this page to monitor NextCure's progress in developing first-in-class immunomedicines and their expanding research into neurodegenerative and chronic disease applications.
NextCure, Inc. (NXTC) has provided a business update and reported its full-year financial results for 2022. The company is focused on three clinical programs, with clinical data updates expected in 2023. Notably, NC525 (LAIR-1 mAb) has dosed its first patient in a Phase 1 trial for acute myeloid leukemia (AML). As of December 31, 2022, NextCure ended the year with approximately $160 million in cash, which is projected to fund operations into mid-2025. However, the company reported a net loss of $74.7 million for 2022, an increase from a $69.4 million loss in 2021, driven by rising research and development costs.
BELTSVILLE, Md., Feb. 7, 2023 (GLOBE NEWSWIRE) -- NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the SVB Securities Global Biopharma Conference on February 15 at 1:40 pm ET. Investors can access a live audio webcast via the company's website, with a replay available for 30 days post-event.
NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to provide new treatment options for patients who do not respond to existing therapies.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced participation in several upcoming investor conferences. The events include the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 3:30 pm ET, the JMP Securities Hematology and Oncology Summit (virtual) on December 6, 2022, at 10:00 am ET, and the Bank of America Securities 2022 Biotech SMID Cap Conference (virtual) on December 8, 2022, at 3:20 pm ET. Webcasts will be available on the company's website, with replays archived for 30 days.
NextCure (NXTC) has announced a collaboration with LegoChem Biosciences (LCB) to co-develop a B7-H4 antibody drug conjugate (ADC) using LCB's ConjuAllTM technology. Both companies will share development costs and profits from any commercialized products. The partnership aims to advance the B7-H4 ADC into clinical trials and explore additional ADC targets. This collaboration is positioned as a significant step in addressing unmet cancer treatment needs, as emphasized by both companies' leadership.
NextCure, a clinical-stage biopharmaceutical company, announced the presentation of initial clinical data from its Phase 1 trial of NC762 at the Society for Immunotherapy of Cancer annual meeting. The trial involved 18 patients with advanced solid tumors and demonstrated safety with no dose-limiting toxicities, suggesting potential immune activation. Additionally, details of a Phase 1b/2 trial for NC410, a combination with pembrolizumab, were shared, targeting 100 patients. NextCure aims to enroll patients with various cancers, with reports on initial data expected in mid-2023.
NextCure, Inc. (Nasdaq: NXTC) has announced the discontinuation of its NC318 program after finding no responses in the trial's amended Phase 2 segment. The company will shift focus to its NC410, NC525, and NC762 programs, including an ongoing combination trial of NC410 with pembrolizumab and a Phase 1 trial of NC525 starting in early 2023. These strategic adjustments are anticipated to extend the company’s cash runway into mid-2025.
As of September 30, 2022, NextCure reported cash equivalents of $169.2 million, down from $219.6 million as of December 31, 2021, resulting in a net loss of $18.9 million for the quarter.
NextCure, Inc. (Nasdaq: NXTC) announced that Dr. Nicholas Short will present a Trials in Progress poster on NC525, a novel immunomedicine, at the upcoming American Society of Hematology (ASH) meeting in New Orleans. NC525 is designed to treat advanced myeloid leukemia (AML) by targeting LAIR-1, present on AML cells. Following promising preclinical results, NextCure has filed an IND application with the FDA and plans to initiate a Phase 1 clinical study in Q1 2023. The presentation is scheduled for December 12, 2022.
NextCure, Inc. (Nasdaq: NXTC) has appointed Dr. Lisa M. Coussens to its Scientific Advisory Board. Dr. Coussens is a proficient translational tumor immunologist with over 20 years of experience in cancer research. She will assist NextCure in enhancing its pipeline of immunomedicines. This strategic addition is expected to bolster NextCure's efforts in immuno-oncology, focusing on tumors and immune response mechanisms. Dr. Coussens' esteemed background includes leadership roles and numerous accolades, positioning her as a key asset for NextCure's future developments in cancer therapies.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its participation in the Society for Immunotherapy of Cancer (SITC) annual meeting from November 8-12, 2022. The company will present data from its Phase 1 clinical study of NC762 and an overview of its NC410 combination study. NC762 targets B7-H4 to inhibit tumor growth, while NC410 blocks immune suppression mediated by LAIR-1. The presentations aim to showcase advancements in NextCure’s immunomedicines aimed at treating cancer.
NextCure, Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company, has initiated a Phase 1b/2 clinical trial for NC410 in combination with Merck's KEYTRUDA® in patients with immune checkpoint refractory or naïve solid tumors. The study aims to explore NC410's potential in treating colorectal, esophageal, endometrial, and head and neck cancers. Key points include: NextCure sponsoring the trial, a supply agreement with Merck, and expected initial data release in mid-2023. NC410 aims to block immune suppression mediated by LAIR-1.
FAQ
What is the current stock price of Nextcure (NXTC)?
What is the market cap of Nextcure (NXTC)?
